Unicycive Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Unicycive Therapeutics, Inc. (NASDAQ: UNCY) is a clinical-stage biotechnology company dedicated to identifying, developing, and commercializing novel therapies for patients suffering from kidney diseases. The company's lead investigational asset is oxylanthanum carbonate (OLC, also known as Renazorb), a next-generation, lanthanum-based phosphate binder designed to treat hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis. OLC aims to significantly reduce the daily pill burden for patients compared to standard-of-care phosphate binders. Unicycive's second pipeline candidate is UNI-494, a selective ATP-sensitive mitochondrial potassium channel activator currently in clinical development for acute kidney injury (AKI) and other cardiorenal indications.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Strengthening commercial infrastructure, advancing market readiness initiatives, and preparing the supply chain to support the potential U.S. launch of OLC in 3Q26.
Expected impact: Successful market entry and commercial adoption of OLC to address the unmet need of hyperphosphatemia in dialysis patients.
Advancing UNI-494, a novel nicotinamide ester derivative and selective ATP-sensitive mitochondrial potassium channel activator, through clinical trials for acute kidney injury (AKI) and cardiorenal indications.
Expected impact: Establishment of clinical proof-of-concept for UNI-494, expanding the company's renal therapy portfolio.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Lotus is responsible for the development, registration filing, approval, and commercialization of Renazorb (Oxylanthanum Carbonate) in the Republic of Korea.
Terms: Unicycive received an upfront payment of $750,000 and is eligible to receive up to $4.45 million in milestone payments, plus tiered royalties on net sales.
Grants Lee's Pharm exclusive rights to develop, market, and commercialize Renazorb (Oxylanthanum Carbonate) in Mainland China, Hong Kong, and select other Asian markets.
Terms: Unicycive received an upfront payment of $1.0 million and is eligible for up to $1.0 million in milestone payments upon product launch in China, alongside tiered royalties.